...Inc. CerRx Inc. Innate Pharma S.A. BioCryst Pharmaceuticals Inc. Johnson & Johnson 4SC AG Medivir AB Bioniz Therapeutics Inc. Codiak BioSciences Inc. Sorrento Therapeutics Inc. Trillium Therapeutics...

...Sciences Inc. (NASDAQ:GILD), I-Mab Biopharma (NASDAQ:IMAB) and Trillium Therapeutics...
...constant Karen Tkach Tuzman Gilead Sciences Inc. Forty Seven Inc. I-Mab Biopharma Trillium Therapeutics...

...Sciences Inc. (NASDAQ:GILD), I-Mab Biopharma (NASDAQ:IMAB) and Trillium Therapeutics...
...TP53) Karen Tkach Tuzman Gilead Sciences Inc. Forty Seven Inc. I-Mab Biopharma Trillium Therapeutics...

...retire in 1H21, after 27 years with the pharma. The company is searching for her successor.Trillium Therapeutics...
...markets and develops HIV, non-alcoholic steatohepatitis and cancer therapies, hires a successor. Danielle Golovin Eli Lilly and Co. Trillium Therapeutics...

...in Trillium following positive dose-escalation dataPfizer Inc. (NYSE:PFE) made a $25 million equity investment in Trillium Therapeutics...

...“Beefing Up Corp Dev” ). Monday’s deal piqued interest in other companies with CD47 assets. Trillium Therapeutics...

...Eat That” ). Since then, at least 11 other companies have announced CD47 programs, including Trillium Therapeutics...
...see “Magrolimab Data Lift Forty Seven Shares” ). Elizabeth S. Eaton, Staff Writer Gilead Sciences Inc. Forty Seven Inc. Trillium Therapeutics...

...when it proposed the offering after hours. Its stock fell $2.55 (10%) to $23.14 Thursday. Trillium Therapeutics...
...factor receptor tyrosine kinase Elizabeth S. Eaton, Staff Writer Blueprint Medicines Corp. Zymeworks Inc. Zai Lab Ltd. Hutchison China MediTech Ltd. Trillium Therapeutics...

...when it proposed the offering after hours. The company fell $2.55 (10%) to $23.14 Thursday. Trillium Therapeutics...
...factor receptor tyrosine kinase Elizabeth S. Eaton, Staff Writer Blueprint Medicines Corp. Zymeworks Inc. Zai Lab Ltd. Hutchison China MediTech Ltd. Trillium Therapeutics...

...wouldn’t raise money until we’re in the clinic,” said Finer. Robert Kirkman, executive chairman of Trillium Therapeutics...